JP7699107B2 - 操作されたリパーゼ改変体 - Google Patents

操作されたリパーゼ改変体 Download PDF

Info

Publication number
JP7699107B2
JP7699107B2 JP2022513058A JP2022513058A JP7699107B2 JP 7699107 B2 JP7699107 B2 JP 7699107B2 JP 2022513058 A JP2022513058 A JP 2022513058A JP 2022513058 A JP2022513058 A JP 2022513058A JP 7699107 B2 JP7699107 B2 JP 7699107B2
Authority
JP
Japan
Prior art keywords
lipase
sequence
seq
recombinant
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545718A (ja
Inventor
チンピン チェン,
ウィリアム ケイシー ハロウズ,
ジュディ ヴィクトリア アントニオ ヴィドゥヤ,
ニッキ デラス,
ステファニー スー ガラニー,
クリステン ジーン ヴァリュウ,
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2022545718A publication Critical patent/JP2022545718A/ja
Priority to JP2025061960A priority Critical patent/JP2025121900A/ja
Application granted granted Critical
Publication of JP7699107B2 publication Critical patent/JP7699107B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883Capsule finishing, e.g. dyeing, aromatising, polishing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003Triacylglycerol lipase (3.1.1.3)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022513058A 2019-08-30 2020-08-28 操作されたリパーゼ改変体 Active JP7699107B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061960A JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962894019P 2019-08-30 2019-08-30
US62/894,019 2019-08-30
PCT/US2020/048405 WO2021041809A1 (en) 2019-08-30 2020-08-28 Engineered lipase variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061960A Division JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Publications (2)

Publication Number Publication Date
JP2022545718A JP2022545718A (ja) 2022-10-28
JP7699107B2 true JP7699107B2 (ja) 2025-06-26

Family

ID=74680918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513058A Active JP7699107B2 (ja) 2019-08-30 2020-08-28 操作されたリパーゼ改変体
JP2025061960A Pending JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061960A Pending JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Country Status (12)

Country Link
US (2) US11987823B2 (https=)
EP (2) EP4501403A3 (https=)
JP (2) JP7699107B2 (https=)
KR (1) KR20220106738A (https=)
CN (2) CN115175995B (https=)
AU (1) AU2020336468B2 (https=)
BR (1) BR112022003705A2 (https=)
CA (1) CA3152763A1 (https=)
ES (1) ES3007439T3 (https=)
IL (1) IL290978A (https=)
MX (1) MX2022002473A (https=)
WO (1) WO2021041809A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102897514B1 (ko) * 2022-03-31 2025-12-08 동아대학교 산학협력단 꿀벌 유래 지질분해 효소 및 이의 용도
CN118480529A (zh) * 2024-05-20 2024-08-13 中国海洋大学 脂肪酶Lip1897-H106Y及其编码基因与在制备DHAPG中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524421A (ja) 2000-02-24 2003-08-19 アルタス バイオロジックス インコーポレイテッド リパーゼ含有組成物およびこれらの使用方法
JP2019089781A (ja) 2009-01-06 2019-06-13 ガレナゲン リミテッド ライアビリティ カンパニー 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
CN101659926A (zh) 1994-06-30 2010-03-03 诺沃奇梅兹有限公司 非毒性、非产毒性、非致病性镰孢属表达系统及所用启动子和终止子
FR2733249B1 (fr) * 1995-04-20 1997-06-06 Biocem Lipase gastrique de chien recombinante et polypeptides derives produits par les plantes, leurs procedes d'obtention et leurs utilisations
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
KR100570935B1 (ko) 1997-01-17 2006-04-13 맥시겐, 인크. 반복적 서열 재조합에 의한 전세포 및 유기체의 개량 방법
US6537746B2 (en) 1997-12-08 2003-03-25 Maxygen, Inc. Method for creating polynucleotide and polypeptide sequences
US6484105B2 (en) 1998-04-02 2002-11-19 Maxyag, Inc. Method for obtaining a plant with a genetic lesion in a gene sequence
IL139093A0 (en) 1998-05-01 2001-11-25 Maxygen Inc Optimization of pest resistance genes using dna shuffling
IL140125A0 (en) 1998-06-17 2002-02-10 Maxygen Inc Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP2002522072A (ja) 1998-08-12 2002-07-23 マキシジェン, インコーポレイテッド 工業用化学薬品の製造のためのモノオキシゲナーゼ遺伝子のdnaシャッフリング。
JP2002526107A (ja) 1998-10-07 2002-08-20 マキシジェン, インコーポレイテッド マイコトキシンの解毒のための核酸を生成するためのdnaシャッフリング
WO2000028018A1 (en) 1998-11-10 2000-05-18 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
JP2003524394A (ja) 1999-02-11 2003-08-19 マキシジェン, インコーポレイテッド ハイスループット質量分析法
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
IL150291A0 (en) 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening
EP1272967A2 (en) 2000-03-30 2003-01-08 Maxygen, Inc. In silico cross-over site selection
JP2004508011A (ja) 2000-04-03 2004-03-18 マキシジェン, インコーポレイテッド スブチリシン変異体
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
JP5319865B2 (ja) 2002-03-01 2013-10-16 コデクシス メイフラワー ホールディングス, エルエルシー 機能的生体分子を同定する方法、システム、およびソフトウェア
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
EP1488335A4 (en) 2002-03-09 2006-11-15 Maxygen Inc OPTIMIZING CROSSOVER POINTS FOR THE ADJUSTED EVOLUTION
US7020762B2 (en) 2002-12-24 2006-03-28 Intel Corporation Method and apparatus for determining a dynamic random access memory page management implementation
JP4588695B2 (ja) 2003-01-30 2010-12-01 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ リパーゼの安定的な変異体
CA3007908A1 (en) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
JP2007502124A (ja) 2003-08-11 2007-02-08 コデクシス, インコーポレイテッド 改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド
PT1809320E (pt) 2004-10-14 2010-10-25 Altus Pharmaceuticals Inc Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
UA97246C2 (ru) 2006-06-15 2012-01-25 Лаборатуа Майоли Спиндле Способ получения липазы, трансформированная клетка дрожжей yarrowia lipolytica, способная вырабатывать липазу, и ее применение
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2250594B1 (en) 2008-02-12 2017-04-19 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
DK3023494T3 (en) 2008-06-13 2019-02-25 Codexis Inc PROCEDURE FOR SYNTHESIS OF POLYNUCLEOTIDE VARIETIES
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
BRPI0922653B8 (pt) 2009-01-29 2021-05-25 Nordmark Arzneimittel Gmbh & Co Kg uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
MY171837A (en) * 2010-09-14 2019-11-01 Univ Putra Malaysia Novel microorganisms producing thermostable lipase from oil contaminated sample and methods thereof
DK2726651T3 (en) 2011-06-28 2019-01-28 Codexis Inc PROTEIN INVARIANT GENERATION BY REGION SHUFFLING
US20150133698A1 (en) 2012-04-20 2015-05-14 Codexis, Inc. Production of fatty alcohols from engineered microorganisms
HUE036947T2 (hu) 2012-05-11 2018-08-28 Codexis Inc Átalakított iminreduktázok és eljárások keton- és aminvegyületek reduktív aminálására
ES2647412T3 (es) 2012-09-14 2017-12-21 REG Life Sciences, LLC Variantes enzimáticas con propiedades de éster sintasa mejoradas
US9665694B2 (en) 2013-01-31 2017-05-30 Codexis, Inc. Methods, systems, and software for identifying bio-molecules with interacting components
LT3237621T (lt) 2014-12-22 2023-09-25 Codexis, Inc. Žmogaus alfa-galaktozidazės variantai
US9821613B2 (en) 2015-07-20 2017-11-21 Bendix Commercial Vehicle Systems Llc Transmitting device with antenna
DE102015114859A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
CN108369922B (zh) 2016-01-26 2023-03-21 应用材料公司 晶片边缘环升降解决方案
EP3645712A4 (en) 2017-06-30 2021-07-07 Codexis, Inc. T7 RNA POLYMERASE VARIANTS
WO2019185612A1 (en) 2018-03-26 2019-10-03 Basf Se Method of reducing soil water repellency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524421A (ja) 2000-02-24 2003-08-19 アルタス バイオロジックス インコーポレイテッド リパーゼ含有組成物およびこれらの使用方法
JP2019089781A (ja) 2009-01-06 2019-06-13 ガレナゲン リミテッド ライアビリティ カンパニー 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Database DDBJ/EMBL/GenBank [online],Accession no. WP_034771740, DEFINITION: lipase [Caldibacillus thermoamylovorans],インターネット <URL: https://www.ncbi.nlm.nih.gov/protein/736768283?sat=58&satkey=92312624>,23-DEC-2014 [検索日 2024.8.5]
Database DDBJ/EMBL/GenBank [online],Accession no. WP_041845597, DEFINITION: lipase [Caldibacillus thermoamylovorans],インターネット <URL: https://www.ncbi.nlm.nih.gov/protein/754285792?sat=58&satkey=137721777>,06-FEB-2015 uploaded [検索日 2024.8.5]
Database DDBJ/EMBL/GenBank [online],Accession no. WP_108898452, DEFINITION: lipase [Caldibacillus thermoamylovorans],インターネット <URL:https://www.ncbi.nlm.nih.gov/protein/1388010833?sat=58&satkey=136424929>,09-MAY-2018 [検索日 2024.8.5]

Also Published As

Publication number Publication date
EP4022049A4 (en) 2023-11-01
US11987823B2 (en) 2024-05-21
ES3007439T3 (en) 2025-03-20
IL290978A (en) 2022-05-01
KR20220106738A (ko) 2022-07-29
EP4501403A3 (en) 2025-05-14
CA3152763A1 (en) 2021-03-04
JP2025121900A (ja) 2025-08-20
EP4501403A2 (en) 2025-02-05
CN115175995B (zh) 2025-05-02
AU2020336468B2 (en) 2026-04-02
MX2022002473A (es) 2022-08-02
US20240263156A1 (en) 2024-08-08
US20210062168A1 (en) 2021-03-04
CN119506248A (zh) 2025-02-25
JP2022545718A (ja) 2022-10-28
WO2021041809A1 (en) 2021-03-04
CN115175995A (zh) 2022-10-11
EP4022049A1 (en) 2022-07-06
EP4022049B1 (en) 2025-01-08
AU2020336468A1 (en) 2022-03-03
BR112022003705A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
JP2025121900A (ja) 操作されたリパーゼ改変体
JP2022103296A (ja) フェニルアラニンアンモニアリアーゼポリペプチド
US20240384251A1 (en) Engineered amylase variants
US12502421B2 (en) Engineered leucine decarboxylases
US11959108B2 (en) Engineered protease variants
US20220389464A1 (en) Engineered tyrosine ammonia lyase
RU2844866C1 (ru) Сконструированные варианты липаз
WO2023154879A2 (en) Engineered oxalate decarboxylases
HK40077280A (en) Engineered lipase variants
HK40077280B (en) Engineered lipase variants
TW202313969A (zh) 經工程化的甲硫胺酸γ解離酶變異體
CN117413057A (zh) 工程化甲硫氨酸γ裂合酶变体
EA050437B1 (ru) Сконструированные лейциндекарбоксилазы

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240510

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240510

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250616

R150 Certificate of patent or registration of utility model

Ref document number: 7699107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150